Merck shares tumble on Q4 earnings miss, weak 2025 guidance

Go back to Merck shares tumble on Q4 earnings miss, weak 2025 guidance

Merck (MRK) PT Lowered to $129 at Goldman Sachs

February 5, 2025 6:35 AM EST

Goldman Sachs analyst Chris Shibutani lowered the price target on Merck (NYSE: MRK) to $129.00 (from $135.00) while maintaining a Buy rating.

The analyst comments "Amidst a backdrop where MRK delivered strong operational performance across the majority of the company's key franchises, the announcement of 2025 guidance, highlighted by the negative impact of the nettlesome dynamics for... More